Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxins: magic bullets or misguided missiles?

E S Vitetta1, P E Thorpe, J W Uhr

  • 1Department of Microbiology, University of Texas Southwestern Medical Center, Dallas 75235.

Trends in Pharmacological Sciences
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemical construction of immunotoxins.

Methods in molecular medicine·2011
Same author

Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia.

Leukemia & lymphoma·2006
Same author

A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro.

Bone marrow transplantation·2006
Same author

Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation.

Cytotherapy·2005
Same author

An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory.

Proceedings of the National Academy of Sciences of the United States of America·2004
Same author

Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.

Neoplasma·2003

Immunotoxin therapy development for cancer, AIDS, and autoimmune diseases is slow due to complex clinical translation. This process requires iterative design and rigorous testing in both lab and animal models before human trials.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Immunotoxins show specific tumor cell killing in vitro and in vivo.
  • Clinical application of immunotoxin therapy has progressed slowly over 13 years.

Purpose of the Study:

  • To discuss the basic and clinical aspects of immunotoxin therapy development.
  • To explain the challenges and multistep process of translating immunotoxin discoveries into clinical treatments.

Main Methods:

  • Iterative design and redesign of immunotoxin molecules based on efficacy and toxicity data.
  • Preclinical evaluation in vitro and in relevant experimental animal models.
  • Phased clinical trials in humans to optimize dosage and identify emerging issues.

Main Results:

Related Experiment Videos

  • The development pathway involves extensive preclinical and clinical evaluation.
  • Challenges in dose regimen optimization and problem-solving frequently emerge during human trials.
  • Animal studies are crucial for modeling and addressing issues identified in clinical settings.

Conclusions:

  • Translating immunotoxin therapy from basic science to clinical practice is a lengthy, interdisciplinary endeavor.
  • Continuous refinement of immunotoxin molecules and rigorous testing are essential for successful therapeutic development.
  • The article highlights the complex journey of immunotoxin therapy from laboratory discovery to potential patient treatment.